De Phung

Statistics

Publications

Citations

5.8K

H-Index

Active since

1998

Affiliations

Astellas Pharma (Netherlands)(Current)

Astellas Pharma (United States)

Institut Gustave Roussy

Cliniques Universitaires Saint-Luc

Université Paris-Sud

De Phung is an author at Astellas Pharma (Netherlands) specializing in medicine, prostate cancer, and metastatic castration-resistant prostate cancer.

Publications per year

1998–2022

Publications

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

Maha Hussain, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2018 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial

David F. Penson, Andrew J. Armstrong, Raoul S. Concepcion et al. · Journal of Clinical Oncology · 2016 · 315 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

Neal D. Shore, Simon Chowdhury, Arnauld Villers et al. · The Lancet Oncology · 2016 · 283 citations

Medicine, Oncology, Pharmacology +14

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

Yohann Loriot, Kurt Miller, Cora N. Sternberg et al. · The Lancet Oncology · 2015 · 191 citations

Medicine, Oncology, Pharmacology +17

1–5 of 25